NCT06939595 - A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer | Biotech Hunter

Enrollment

606

Participants

Timeline

Start Date

January 30, 2025

Primary Completion Date

February 28, 2027

Study Completion Date

July 31, 2028

Conditions

Non Squamous Non Small Cell Lung Cancer

Interventions

DRUG

CT-P51

CT-P51 200mg with pemetrexed and cisplatin or carboplatin will be administered every 3 weeks for a maximum of 4 cycles followed by CT-P51 or Keytruda and pemetrexed every 3 weeks

DRUG

EU-approved Keytruda

Keytruda 200mg with pemetrexed and cisplatin or carboplatin will be administered every 3 weeks for a maximum of 4 cycles followed by CT-P51 or Keytruda and pemetrexed every 3 weeks

Trial Locations (1)

Unknown

RECRUITING

"ltd Institute of Clinical Oncology", Tbilisi